Phony internet pharmacies and other illegitimate outlets are driving the massive counterfeit medicine market to consumers worldwide, according to a recent report released today by Cambridge Consultants. Contributing to its findings on the serious issues relating to counterfeit medicine and the diversion of legitimate products, the leading technology product design and development firm conducted in-depth interviews with leaders from pharmaceutical and biotech businesses as well as technology developers and industry bodies. As part of the report, Cambridge Consultants identified the urgent need for more consumer education along with new and improved regulatory standards to address this growing public health threat associated with counterfeit medicine. In addition, the report included recommendations for solutions that businesses can use to address the global drug counterfeiting epidemic.
“Although there has been some debate around the size of the worldwide counterfeit medicine market that has been estimated at $75 billion and upward, one cannot dispute that the unregulated growth of internet pharmacies will only contribute to this problem,” said Rainuka Gupta, Group Manager of Medical Technologies at Cambridge Consultants. “Our research concluded that this presents both a dual threat to consumers and the industry alike. Easier access to cheaper drugs has exposed consumers to dangerous mixes of fake drugs and placebos. Meanwhile, pharmaceutical companies risk losing credibility and regulatory bodies risk losing control with the spread of these counterfeit medicines. As an industry, we need to better educate consumers on the threats associated with fake drugs, but we also must work together to coordinate and implement technologies that can detect and deter counterfeiters”
Already a global problem, especially in Africa and Southeast Asia where the World Health Organization (WHO) has estimated that about 50 percent of medicines could be fake, counterfeit drugs have also been flooding the US market. In 2009, the US Customs and Border Protection Agency stated that the value of seizures of counterfeit pharmaceuticals had increased by 500 percent over the previous 3 years. Despite increased efforts to stop the flow of counterfeit medicine, the growth of internet pharmacies has exacerbated the issue and put consumers at further risk. According to LegitScript, which monitors web sites that facilitate the sale of prescription drugs, approximately 97 percent of the nearly 50,000 pharmacy websites in its database do not meet their standards for being verified as a legitimate pharmacy (licensed pharmacy, appropriate registrations, requiring a valid prescription, etc).
“As an advocacy organization, we were pleased to participate in this research and we thank Cambridge Consultants for bringing attention to the growing issues around the counterfeit medicine market,” said Andrew Emmett, Managing Director for Science & Regulatory Affairs for Biotechnology Industry Organization (BIO). “While there have been recent improvements in enforcements and regulations, there continues to be a need for a comprehensive private-public response to criminal counterfeiting focusing on education, legislation, enforcement, investigation and international collaboration.”
Cambridge Consultants organized a panel on the topic during the 2010 BIO International Convention earlier this year, which featured industry leaders from Amgen, Genzyme and BIO to discuss measures to address counterfeit medicine. Currently, there are three different types of technologies that can be deployed (anti-tamper packaging, serialization and authentication) to fight against counterfeit pharmaceuticals. However, due to the complex, global nature of counterfeiting and diversion carried out by organized criminals, the panel and research participants all agreed that collaboration among different stakeholders, including manufacturers, supply chain and law enforcement, is critical to address the problem.
Against the backdrop of a need for wider education concerning the dangers behind buying drugs from internet pharmacies, the research by Cambridge Consultants highlighted the need for today’s technologies to tie into business processes to form an integrated solution that continuously evolves, especially considering that counterfeiters have demonstrated that they can quickly adjust and respond to any one-off approaches. A key complexity of tackling anti-counterfeit and product diversion is that it needs to be addressed globally at a system level, otherwise criminals will simply move to less well protected markets. As a result, the report states that this requires everything from coordination of customs and law enforcement, through the adoption of legislation along with public education campaigns. In addition, the report also highlights how companies can take concrete steps to address threats to their businesses and their customers based on the product-specific risks.
Cambridge Consultants is one of the leading design and development companies with a long history of working on new products for many of the world’s leading pharmaceutical and drug delivery companies. Additionally, Cambridge Consultants has over 20 years of experience in developing and integrating authentication systems and secure systems for clients spanning the pharmaceutical, biotechnology, consumer electronics and consumer markets. The company’s independent approach means that it can design and implement layered anti-counterfeit and diversion solutions using a range of technologies, appropriate to the business need and existing or new brand protection strategies.
Copies of the white paper can be downloaded by registering here
Notes for editors:
Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology critical issues for clients worldwide. For 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of over 300 engineers, designers, scientists and consultants, in offices in Cambridge (UK) and Boston (USA), Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, transport, energy, cleantech and wireless communications.
Throughout 2010, Cambridge Consultants celebrates its 50th year in business. Created by three Cambridge graduates in 1960, the company has grown into a leading technology business, renowned worldwide for its ability to solve technical problems and provide innovative, practical solutions to commercial issues. In 2009, the company was awarded the prestigious Queen’s Award for Enterprise in International Trade. For more information visit: www.CambridgeConsultants.com
Cambridge Consultants is part of Altran, the European leader in innovation and high technology consulting. The Group’s 17,500 consultants, operating worldwide, cover the entire range of engineering specialities, including electronics, information technology, quality and organisation. Altran offers its clients ongoing support throughout the innovation cycle, from technology watch, applied basic research and management consulting to industrial systems engineering and information systems. The Group provides services to most industries, including the automotive, aeronautics, space, life sciences and telecommunications sectors. Founded in 1982, Altran operates in 20 priority countries. In 2008, it generated a turnover of €1,650 million. For more information visit: www.altran.com
For further information:
Press & Communications Manager
Tel: +44 1223 420024
Tel: +44 20 8408 8000
Tel: +1 617 443 9933 etx:356